Extended Data Fig. 7: Expression and function of Siglec-15 in mouse tumors.
From: Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
a, Siglec-15 mRNA expression in tumors from indicated mouse models by comparison to B7-H1, analyzed from the CrownBio MuBase database. b, Siglec-15 mRNA levels in tumors of B16-GMCSF and GL261 model was determined by RT–PCR on day 14 after inoculation. Spleen from a S15KO mouse was used as negative control. Data are relative levels to reference gene RPL13a. c, Flow cytometric analysis of Siglec-15 expression on infiltrating immune cell subsets of B16-GMCSF tumors from Siglec-15 WT and KO mice on day 14 after inoculation. Data are representative of two independent experiments. d,e, B16-GMCSF tumor cells at 1.5 × 106 per mouse or wild type B16 tumor cells at 1 × 106 per mouse were injected subcutaneously into Siglec-15 WT, KO or LysM-Cre KO as indicated. Tumor growth was measured regularly and is shown as the mean tumor diameter ± s.e.m. (n = 6 mice per group). P values by two-way ANOVA (n.s., not significant; P = 0.3180).
